[HTML] springer.comFull View

[HTML][HTML] Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study

H Zhou, D Sun, S Song, Y Niu, Y Zhang, H Lan, J Cui… - Discover Oncology, 2024 - Springer
Background Immune checkpoint inhibitors (ICIs), especially those targeting programmed cell
death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), have introduced a new …
相关文章

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study.

H Zhou, D Sun, S Song, Y Niu, Y Zhang… - Discover …, 2024 - search.ebscohost.com
Abstract Background: Immune checkpoint inhibitors (ICIs), especially those targeting
programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), have …

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study.

H Zhou, D Sun, S Song, Y Niu, Y Zhang, H Lan… - Discover …, 2024 - europepmc.org
Background Immune checkpoint inhibitors (ICIs), especially those targeting programmed cell
death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), have introduced a new …

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study

H Zhou, D Sun, S Song, Y Niu, Y Zhang… - Discover …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs), especially those targeting programmed cell
death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), have introduced a new …
[HTML] nih.gov

[HTML][HTML] Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study

H Zhou, D Sun, S Song, Y Niu, Y Zhang, H Lan… - Discover …, 2024 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs), especially those targeting programmed cell
death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), have introduced a new …